Paxton
Maeder-York

The engineer who turned personal stakes into public good

Most people who build AI companies in healthcare point to a statistic. Paxton Maeder-York points to his brother. Born via in vitro fertilization, his brother is the walking, breathing reason Paxton left surgical robotics behind and spent the next four years building machine learning models for fertility clinics. The mission isn't abstract for him. It's sitting at Thanksgiving dinner.

That specificity matters because the IVF industry, for all its clinical complexity, had been running on gut instinct and spreadsheets. One in eight couples face infertility. Success rates vary wildly between clinics, between doctors, between cycles. The data existed - it just wasn't being used. Paxton looked at that gap and saw the same problem he'd been solving at Auris Health: a situation where physical skill was being asked to substitute for information that machines could provide.

At Auris, he was one of the earliest engineers and the company's first product manager, building robotic systems to treat lung cancer - a disease that had taken several of his grandparents. That company sold to Johnson & Johnson for $3.4 billion in 2019. Paxton didn't cash out and retire. He enrolled in two graduate programs simultaneously at Harvard and then went to work in product at Google X's robotics division (now called Intrinsic). He was doing what engineers do: learning the next system.

In 2020, armed with an S.M. in Computational Science and an MBA from Harvard Business School, he founded Alife Health. Within months, the company won the Grand Prize at the HBS New Venture Competition. By May 2021, Lux Capital led a $9.5M seed round. Anne Wojcicki, the 23andMe founder, and Fred Moll, who founded Intuitive Surgical, wrote checks. These are not casual backers. They're people who have built medical device and genomics empires - and they recognized a pattern.

Five products, one very specific problem

Most AI health startups announce a platform and ship a demo. Alife shipped five distinct tools, each targeting a different friction point in the IVF workflow. Stim Assist uses data from 40,000+ prior cases to optimize hormone dosing - helping doctors retrieve up to 20% more eggs per patient while cutting medication costs by around $1,000 per cycle. Schedule Predict reduces over-capacity clinic days by 65%. Embryo Assist standardizes grading and can cut nursing workload by 90%. These aren't rounding errors. They're structural changes to how clinics operate.

The approach reflects Paxton's background in biorobotics as much as it does in machine learning. He studied under Professor Rob Howe in Harvard's Biorobotics Lab, where the question was always: how does a machine translate human intent into physical precision? Applied to embryology, the question becomes: how does a model translate vast clinical data into a decision a doctor can trust? The word Paxton keeps returning to is "enhancing" - the AI as amplifier, not replacement.

$31.5M and the question of what comes next

In March 2022, Union Square Ventures led Alife's $22M Series A. The total capitalization reached $31.5 million across two rounds from 13 investors. By 2022, the World Economic Forum named Alife a Technology Pioneer. By 2024, Fast Company listed it among the most innovative companies in the US - specifically in the "small and mighty" category, which covers teams of 50 or fewer employees. For a company attacking a problem this intractable, that's a meaningful signal.

In October 2024, Paxton made a deliberate move: he stepped back from the CEO role and joined the board of directors. Melissa Teran, who had been serving as COO and Head of Product, became CEO. The transition was his call. The company he built was ready for a different kind of leader - one focused on scaling operations rather than founding a vision. Paxton's kind of discipline includes knowing when to hand over the controls.

Embryo Predict, Alife's embryo selection AI, received its CE Mark under European Medical Device Regulation in 2025 - a significant regulatory milestone that opens the European market and signals a broader global expansion. The company has moved from scrappy San Francisco startup to internationally regulated medical device maker. That trajectory, from HBS competition winner to WEF pioneer to CE-marked product, is not accidental. It's what happens when mission and mechanism line up.

The personal equation

Paxton's public persona is quiet. His Instagram has fewer than 1,000 followers. He doesn't hold court at TechCrunch Disrupt. The signals he sends are technical: a podcast about the data architecture of IVF platforms, an interview about interpretable AI models in clinical settings, a press release about a CE Mark. For a generation of founders who confuse visibility with credibility, he's a useful counterexample.

What's striking, in all the interviews, is how consistently the same two things appear: the specific loss of grandparents to lung cancer (Auris), and the specific existence of his IVF-born brother (Alife). He doesn't talk in generalities about healthcare or disruption. He talks about the people in his life who needed something that technology could have delivered better. That's not a brand narrative. That's an operating principle.

One in eight couples face infertility. IVF remains expensive, emotionally brutal, and statistically uncertain. The idea that AI could tilt those odds - retrieve one more viable embryo, predict one more successful transfer, save one more couple from another cycle - is the thing Paxton Maeder-York has been working toward since 2020. His brother is proof it's worth the effort.

Five tools that changed what IVF clinics know

$31.5M across two rounds

Earned, not announced